Abstract
Aims: PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer. Materials and methods: In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer. Results: The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38). Conclusion: We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 333-337 |
| Number of pages | 5 |
| Journal | Clinical Oncology |
| Volume | 18 |
| Issue number | 4 |
| Early online date | 15 Mar 2006 |
| DOIs | |
| Publication status | Published - 1 May 2006 |
| Externally published | Yes |
